JP2016523560A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016523560A5 JP2016523560A5 JP2016525414A JP2016525414A JP2016523560A5 JP 2016523560 A5 JP2016523560 A5 JP 2016523560A5 JP 2016525414 A JP2016525414 A JP 2016525414A JP 2016525414 A JP2016525414 A JP 2016525414A JP 2016523560 A5 JP2016523560 A5 JP 2016523560A5
- Authority
- JP
- Japan
- Prior art keywords
- rna
- cell
- target nucleic
- nucleic acid
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 47
- 210000004027 cell Anatomy 0.000 claims description 44
- 108091033409 CRISPR Proteins 0.000 claims description 31
- 101710163270 Nuclease Proteins 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 26
- 230000002950 deficient Effects 0.000 claims description 22
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 102000004169 proteins and genes Human genes 0.000 claims description 19
- 108020005004 Guide RNA Proteins 0.000 claims description 12
- 230000000295 complement effect Effects 0.000 claims description 12
- 108020004414 DNA Proteins 0.000 claims description 6
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims description 5
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims description 5
- 230000027455 binding Effects 0.000 claims description 5
- 230000004927 fusion Effects 0.000 claims description 5
- 238000013518 transcription Methods 0.000 claims description 5
- 230000035897 transcription Effects 0.000 claims description 5
- 238000010354 CRISPR gene editing Methods 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims 61
- 102000039446 nucleic acids Human genes 0.000 claims 61
- 150000007523 nucleic acids Chemical class 0.000 claims 60
- 102000052510 DNA-Binding Proteins Human genes 0.000 claims 21
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims 18
- 101710096438 DNA-binding protein Proteins 0.000 claims 17
- 101000709520 Chlamydia trachomatis serovar L2 (strain 434/Bu / ATCC VR-902B) Atypical response regulator protein ChxR Proteins 0.000 claims 11
- 239000002773 nucleotide Substances 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 230000002411 adverse Effects 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 4
- 108700020911 DNA-Binding Proteins Proteins 0.000 claims 4
- 230000004570 RNA-binding Effects 0.000 claims 4
- 108020005196 Mitochondrial DNA Proteins 0.000 claims 2
- 108020005202 Viral DNA Proteins 0.000 claims 2
- 210000004102 animal cell Anatomy 0.000 claims 2
- 230000008045 co-localization Effects 0.000 claims 2
- 230000001276 controlling effect Effects 0.000 claims 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims 2
- 108091006106 transcriptional activators Proteins 0.000 claims 2
- 210000005253 yeast cell Anatomy 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 10
- 238000010586 diagram Methods 0.000 description 9
- 125000006850 spacer group Chemical group 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 241000589602 Francisella tularensis Species 0.000 description 4
- 229940118764 francisella tularensis Drugs 0.000 description 4
- 241000032681 Gluconacetobacter Species 0.000 description 3
- 241000194019 Streptococcus mutans Species 0.000 description 3
- 108091027544 Subgenomic mRNA Proteins 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 241000589875 Campylobacter jejuni Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 241000193985 Streptococcus agalactiae Species 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000005782 double-strand break Effects 0.000 description 2
- 238000010362 genome editing Methods 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000006780 non-homologous end joining Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 241001041760 Acidothermus cellulolyticus 11B Species 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 241000186063 Arthrobacter Species 0.000 description 1
- 241000589941 Azospirillum Species 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000606124 Bacteroides fragilis Species 0.000 description 1
- 241000586987 Bifidobacterium dentium Bd1 Species 0.000 description 1
- 241001209261 Bifidobacterium longum DJO10A Species 0.000 description 1
- 241001453247 Campylobacter jejuni subsp. doylei Species 0.000 description 1
- 241000941427 Campylobacter lari RM2100 Species 0.000 description 1
- 241001034636 Capnocytophaga ochracea DSM 7271 Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241001509504 Clostridium botulinum F Species 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 241001487058 Corynebacterium efficiens YS-314 Species 0.000 description 1
- 241000186226 Corynebacterium glutamicum Species 0.000 description 1
- 241000671338 Corynebacterium glutamicum R Species 0.000 description 1
- 241001525611 Corynebacterium kroppenstedtii DSM 44385 Species 0.000 description 1
- 241000605765 Desulfovibrio salexigens Species 0.000 description 1
- 241000933091 Dinoroseobacter shibae DFL 12 = DSM 16493 Species 0.000 description 1
- 241000608038 Fibrobacter succinogenes subsp. succinogenes S85 Species 0.000 description 1
- 241000359186 Finegoldia magna ATCC 29328 Species 0.000 description 1
- 241000382842 Flavobacterium psychrophilum Species 0.000 description 1
- 108050008753 HNH endonucleases Proteins 0.000 description 1
- 102000000310 HNH endonucleases Human genes 0.000 description 1
- 241001453258 Helicobacter hepaticus Species 0.000 description 1
- 101000976622 Homo sapiens Zinc finger protein 42 homolog Proteins 0.000 description 1
- 241001063987 Kribbella flavida Species 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 1
- 241001427851 Lactobacillus salivarius UCC118 Species 0.000 description 1
- 241001193656 Legionella pneumophila str. Paris Species 0.000 description 1
- 241000186805 Listeria innocua Species 0.000 description 1
- 241001378931 Methanococcus maripaludis C7 Species 0.000 description 1
- 241000825684 Mycobacterium abscessus ATCC 19977 Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000204022 Mycoplasma gallisepticum Species 0.000 description 1
- 241000107400 Mycoplasma mobile 163K Species 0.000 description 1
- 241001135743 Mycoplasma penetrans Species 0.000 description 1
- 241000051161 Mycoplasma synoviae 53 Species 0.000 description 1
- 241000156211 Neisseria meningitidis 053442 Species 0.000 description 1
- 241000529650 Neisseria meningitidis Z2491 Species 0.000 description 1
- 241000554781 Neisseria meningitidis alpha14 Species 0.000 description 1
- 241001648684 Nitrobacter hamburgensis X14 Species 0.000 description 1
- 101150085710 OCT4 gene Proteins 0.000 description 1
- 241000606856 Pasteurella multocida Species 0.000 description 1
- 241000549884 Persephonella marina EX-H1 Species 0.000 description 1
- 241000695265 Pseudoalteromonas atlantica T6c Species 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 241000647111 Rhodococcus erythropolis PR4 Species 0.000 description 1
- 241001459443 Rhodococcus jostii RHA1 Species 0.000 description 1
- 241001113889 Rhodococcus opacus B4 Species 0.000 description 1
- 241000190932 Rhodopseudomonas Species 0.000 description 1
- 241001303434 Rhodopseudomonas palustris BisB18 Species 0.000 description 1
- 241000134686 Rhodospirillum rubrum ATCC 11170 Species 0.000 description 1
- 241000516659 Roseiflexus Species 0.000 description 1
- 241000504328 Roseiflexus castenholzii DSM 13941 Species 0.000 description 1
- 241000933177 Shewanella pealeana ATCC 700345 Species 0.000 description 1
- 241001496704 Slackia heliotrinireducens DSM 20476 Species 0.000 description 1
- 241001478878 Streptobacillus Species 0.000 description 1
- 241001288016 Streptococcus gallolyticus Species 0.000 description 1
- 241001147754 Streptococcus gordonii str. Challis Species 0.000 description 1
- 241000672607 Streptococcus mutans NN2025 Species 0.000 description 1
- 241000103155 Streptococcus pyogenes MGAS10270 Species 0.000 description 1
- 241001520169 Streptococcus pyogenes MGAS315 Species 0.000 description 1
- 241001332083 Streptococcus pyogenes MGAS6180 Species 0.000 description 1
- 241000103156 Streptococcus pyogenes MGAS9429 Species 0.000 description 1
- 241001496716 Streptococcus pyogenes NZ131 Species 0.000 description 1
- 241001217892 Streptococcus thermophilus CNRZ1066 Species 0.000 description 1
- 241001633172 Streptococcus thermophilus LMD-9 Species 0.000 description 1
- 241000079831 Streptococcus thermophilus LMG 18311 Species 0.000 description 1
- 241000192593 Synechocystis sp. PCC 6803 Species 0.000 description 1
- 241001496699 Thermomonospora curvata DSM 43183 Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000847071 Verminephrobacter eiseniae EF01-2 Species 0.000 description 1
- 241000605941 Wolinella Species 0.000 description 1
- 241000883281 [Clostridium] cellulolyticum H10 Species 0.000 description 1
- 241001531188 [Eubacterium] rectale Species 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000037006 agalactosis Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 108020001778 catalytic domains Proteins 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012350 deep sequencing Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940059406 lactobacillus rhamnosus gg Drugs 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940051027 pasteurella multocida Drugs 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361844844P | 2013-07-10 | 2013-07-10 | |
| US61/844,844 | 2013-07-10 | ||
| PCT/US2014/045700 WO2015006294A2 (en) | 2013-07-10 | 2014-07-08 | Orthogonal cas9 proteins for rna-guided gene regulation and editing |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019238875A Division JP7153992B2 (ja) | 2013-07-10 | 2019-12-27 | Ｒｎａ誘導性遺伝子制御および編集のための直交性ｃａｓ９タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016523560A JP2016523560A (ja) | 2016-08-12 |
| JP2016523560A5 true JP2016523560A5 (https=) | 2017-07-27 |
| JP6718813B2 JP6718813B2 (ja) | 2020-07-08 |
Family
ID=52280701
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016525414A Active JP6718813B2 (ja) | 2013-07-10 | 2014-07-08 | Ｒｎａ誘導性遺伝子制御および編集のための直交性ｃａｓ９タンパク質 |
| JP2019238875A Active JP7153992B2 (ja) | 2013-07-10 | 2019-12-27 | Ｒｎａ誘導性遺伝子制御および編集のための直交性ｃａｓ９タンパク質 |
| JP2022159833A Pending JP2022176275A (ja) | 2013-07-10 | 2022-10-03 | Ｒｎａ誘導性遺伝子制御および編集のための直交性ｃａｓ９タンパク質 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019238875A Active JP7153992B2 (ja) | 2013-07-10 | 2019-12-27 | Ｒｎａ誘導性遺伝子制御および編集のための直交性ｃａｓ９タンパク質 |
| JP2022159833A Pending JP2022176275A (ja) | 2013-07-10 | 2022-10-03 | Ｒｎａ誘導性遺伝子制御および編集のための直交性ｃａｓ９タンパク質 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US10329587B2 (https=) |
| EP (2) | EP3666892A1 (https=) |
| JP (3) | JP6718813B2 (https=) |
| KR (2) | KR102285485B1 (https=) |
| CN (2) | CN110819658B (https=) |
| AU (4) | AU2014287397B2 (https=) |
| BR (1) | BR112016000571B1 (https=) |
| CA (2) | CA3218040A1 (https=) |
| IL (3) | IL282489B (https=) |
| RU (3) | RU2748433C2 (https=) |
| SG (3) | SG11201600060VA (https=) |
| WO (1) | WO2015006294A2 (https=) |
Families Citing this family (137)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2831144A1 (en) | 2011-03-23 | 2012-09-27 | Pioneer Hi-Bred International, Inc. | Methods for producing a complex transgenic trait locus |
| US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| AU2013266968B2 (en) | 2012-05-25 | 2017-06-29 | Emmanuelle CHARPENTIER | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
| PL3360964T3 (pl) | 2012-12-06 | 2020-03-31 | Sigma-Aldrich Co. Llc | Modyfikacja i regulacja genomu oparta na crispr |
| DK2931891T3 (da) * | 2012-12-17 | 2019-08-19 | Harvard College | Rna-styret modificering af menneskelige genomer |
| DK3456831T3 (da) | 2013-04-16 | 2021-09-06 | Regeneron Pharma | Målrettet modifikation af rottegenom |
| US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| CN120574876A (zh) | 2013-08-22 | 2025-09-02 | 纳幕尔杜邦公司 | 使用向导rna/cas内切核酸酶系统的植物基因组修饰及其使用方法 |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| EP3988649B1 (en) | 2013-09-18 | 2024-11-27 | Kymab Limited | Methods, cells and organisms |
| US11326209B2 (en) * | 2013-11-07 | 2022-05-10 | Massachusetts Institute Of Technology | Cell-based genomic recorded accumulative memory |
| CN106459995B (zh) | 2013-11-07 | 2020-02-21 | 爱迪塔斯医药有限公司 | 使用统治型gRNA的CRISPR相关方法和组合物 |
| KR102170502B1 (ko) | 2013-12-11 | 2020-10-28 | 리제너론 파마슈티칼스 인코포레이티드 | 게놈의 표적화된 변형을 위한 방법 및 조성물 |
| US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| US11028388B2 (en) | 2014-03-05 | 2021-06-08 | Editas Medicine, Inc. | CRISPR/Cas-related methods and compositions for treating Usher syndrome and retinitis pigmentosa |
| US11339437B2 (en) | 2014-03-10 | 2022-05-24 | Editas Medicine, Inc. | Compositions and methods for treating CEP290-associated disease |
| US11141493B2 (en) | 2014-03-10 | 2021-10-12 | Editas Medicine, Inc. | Compositions and methods for treating CEP290-associated disease |
| ES2745769T3 (es) | 2014-03-10 | 2020-03-03 | Editas Medicine Inc | Procedimientos y composiciones relacionados con CRISPR/CAS para tratar la amaurosis congénita de Leber 10 (LCA10) |
| EP3122880B1 (en) | 2014-03-26 | 2021-05-05 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating sickle cell disease |
| EP3540061A1 (en) | 2014-04-02 | 2019-09-18 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating primary open angle glaucoma |
| US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
| MX2017002930A (es) | 2014-09-12 | 2017-06-06 | Du Pont | Generacion de sitios de integracion especifica de sitio para loci de rasgos complejos en maiz y soja, y metodos de uso. |
| AU2015330699B2 (en) | 2014-10-10 | 2021-12-02 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| GB201418965D0 (https=) | 2014-10-24 | 2014-12-10 | Ospedale San Raffaele And Fond Telethon | |
| EP4464338A3 (en) | 2014-11-07 | 2025-02-12 | Editas Medicine, Inc. | Systems for improving crispr/cas-mediated genome-editing |
| CA2969619A1 (en) | 2014-12-03 | 2016-06-09 | Agilent Technologies, Inc. | Guide rna with chemical modifications |
| CN116059378A (zh) | 2014-12-10 | 2023-05-05 | 明尼苏达大学董事会 | 用于治疗疾病的遗传修饰的细胞、组织和器官 |
| BR112017017260A2 (pt) | 2015-03-27 | 2018-04-17 | Du Pont | construções de dna, vetor, célula, plantas, semente, método de expressão de rna e método de modificação de local alvo |
| KR102888521B1 (ko) | 2015-04-06 | 2025-11-19 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | Crispr/cas-매개 유전자 조절을 위한 화학적으로 변형된 가이드 rna |
| JP2018522249A (ja) * | 2015-04-24 | 2018-08-09 | エディタス・メディシン、インコーポレイテッド | Ｃａｓ９分子／ガイドｒｎａ分子複合体の評価 |
| CA2986310A1 (en) | 2015-05-11 | 2016-11-17 | Editas Medicine, Inc. | Optimized crispr/cas9 systems and methods for gene editing in stem cells |
| AU2016263026A1 (en) * | 2015-05-15 | 2017-11-09 | Pioneer Hi-Bred International, Inc. | Guide RNA/Cas endonuclease systems |
| CN108025188A (zh) | 2015-06-01 | 2018-05-11 | 天普大学-联邦高等教育系统 | 用于hiv感染的rna导向治疗的方法和组合物 |
| CN108026526B (zh) | 2015-06-09 | 2023-05-12 | 爱迪塔斯医药公司 | 用于改善移植的crispr/cas相关方法和组合物 |
| WO2016205745A2 (en) * | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Cell sorting |
| GB2592821B (en) | 2015-07-31 | 2022-01-12 | Univ Minnesota | Modified cells and methods of therapy |
| EP3353296B1 (en) | 2015-09-24 | 2020-11-04 | Editas Medicine, Inc. | Use of exonucleases to improve crispr/cas-mediated genome editing |
| IL310721B2 (en) | 2015-10-23 | 2025-11-01 | Harvard College | Nucleobase editors and uses thereof |
| WO2017074943A1 (en) * | 2015-10-27 | 2017-05-04 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of inducibly targeting chromatin effectors and compositions for use in the same |
| CA3005968A1 (en) | 2015-11-23 | 2017-06-01 | The Regents Of The University Of California | Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9 |
| MX2018008345A (es) | 2016-01-11 | 2018-12-06 | Univ Leland Stanford Junior | Proteínas quiméricas y métodos de inmunoterapia. |
| IL260532B2 (en) | 2016-01-11 | 2023-12-01 | Univ Leland Stanford Junior | Chimeric proteins- containing systems and uses thereof in regulating gene expression |
| WO2017122096A1 (en) * | 2016-01-15 | 2017-07-20 | Astrazeneca Ab | Gene modification assays |
| US11512311B2 (en) | 2016-03-25 | 2022-11-29 | Editas Medicine, Inc. | Systems and methods for treating alpha 1-antitrypsin (A1AT) deficiency |
| US11597924B2 (en) | 2016-03-25 | 2023-03-07 | Editas Medicine, Inc. | Genome editing systems comprising repair-modulating enzyme molecules and methods of their use |
| AU2017250265B2 (en) * | 2016-04-12 | 2023-08-17 | CarryGenes Bioengineering | Methods for creating synthetic chromosomes having gene regulatory systems and uses thereof |
| JP7497139B2 (ja) | 2016-04-12 | 2024-06-10 | キャリージーンズ バイオエンジニアリング | 生合成経路を発現する合成染色体の作成方法及びその使用 |
| US11236313B2 (en) | 2016-04-13 | 2022-02-01 | Editas Medicine, Inc. | Cas9 fusion molecules, gene editing systems, and methods of use thereof |
| US10767175B2 (en) | 2016-06-08 | 2020-09-08 | Agilent Technologies, Inc. | High specificity genome editing using chemically modified guide RNAs |
| WO2017222834A1 (en) * | 2016-06-10 | 2017-12-28 | City Of Hope | Compositions and methods for mitochondrial genome editing |
| BR112019001887A2 (pt) | 2016-08-02 | 2019-07-09 | Editas Medicine Inc | composições e métodos para o tratamento de doença associada a cep290 |
| CN110214183A (zh) | 2016-08-03 | 2019-09-06 | 哈佛大学的校长及成员们 | 腺苷核碱基编辑器及其用途 |
| WO2018031683A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
| CN106282228A (zh) * | 2016-08-19 | 2017-01-04 | 苏州兰希亚生物科技有限公司 | 一种基因点突变修复的方法 |
| US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| US20190225974A1 (en) | 2016-09-23 | 2019-07-25 | BASF Agricultural Solutions Seed US LLC | Targeted genome optimization in plants |
| KR102622411B1 (ko) | 2016-10-14 | 2024-01-10 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
| CN110520530A (zh) * | 2016-10-18 | 2019-11-29 | 明尼苏达大学董事会 | 肿瘤浸润性淋巴细胞和治疗方法 |
| EP3535396A1 (en) | 2016-11-01 | 2019-09-11 | Novartis AG | Methods and compositions for enhancing gene editing |
| EP3555297A1 (en) | 2016-12-19 | 2019-10-23 | Editas Medicine, Inc. | Assessing nuclease cleavage |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| JP7229923B2 (ja) | 2017-01-06 | 2023-02-28 | エディタス・メディシン、インコーポレイテッド | ヌクレアーゼ切断を評価する方法 |
| WO2018140899A1 (en) * | 2017-01-28 | 2018-08-02 | Inari Agriculture, Inc. | Novel plant cells, plants, and seeds |
| TW201839136A (zh) | 2017-02-06 | 2018-11-01 | 瑞士商諾華公司 | 治療血色素異常症之組合物及方法 |
| US11866699B2 (en) | 2017-02-10 | 2024-01-09 | University Of Washington | Genome editing reagents and their use |
| US12440578B2 (en) | 2017-02-22 | 2025-10-14 | Io Biosciences, Inc. | Nucleic acid constructs comprising gene editing multi-sites and uses thereof |
| US10828330B2 (en) | 2017-02-22 | 2020-11-10 | IO Bioscience, Inc. | Nucleic acid constructs comprising gene editing multi-sites and uses thereof |
| EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
| US12390514B2 (en) | 2017-03-09 | 2025-08-19 | President And Fellows Of Harvard College | Cancer vaccine |
| US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
| WO2018170184A1 (en) | 2017-03-14 | 2018-09-20 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
| WO2018170015A1 (en) * | 2017-03-14 | 2018-09-20 | The Regents Of The University Of California | Engineering crispr cas9 immune stealth |
| KR20240116572A (ko) | 2017-03-23 | 2024-07-29 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제 |
| EP3617311B1 (en) * | 2017-03-30 | 2024-11-20 | Kyoto University | Method for inducing exon skipping by genome editing |
| KR102746223B1 (ko) | 2017-04-20 | 2024-12-27 | 이제네시스, 인크. | 유전자 변형 동물의 생성 방법 |
| US11499151B2 (en) | 2017-04-28 | 2022-11-15 | Editas Medicine, Inc. | Methods and systems for analyzing guide RNA molecules |
| WO2018208998A1 (en) | 2017-05-10 | 2018-11-15 | The Regents Of The University Of California | Directed editing of cellular rna via nuclear delivery of crispr/cas9 |
| EP3622070A2 (en) | 2017-05-10 | 2020-03-18 | Editas Medicine, Inc. | Crispr/rna-guided nuclease systems and methods |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| MX2019014640A (es) | 2017-06-09 | 2020-10-05 | Editas Medicine Inc | Nucleasas de repeticiones palíndromicas agrupadas y regularmente interespaciadas de proteina asociada 9 (cas9) genomanipuladas. |
| US20200140896A1 (en) | 2017-06-30 | 2020-05-07 | Novartis Ag | Methods for the treatment of disease with gene editing systems |
| EP3645021A4 (en) | 2017-06-30 | 2021-04-21 | Intima Bioscience, Inc. | ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY |
| US11866726B2 (en) | 2017-07-14 | 2024-01-09 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
| CN111801345A (zh) | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物 |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| AU2018338318B2 (en) | 2017-09-21 | 2022-12-22 | Massachusetts Institute Of Technology | Systems, methods, and compositions for targeted nucleic acid editing |
| US11603536B2 (en) | 2017-09-29 | 2023-03-14 | Inari Agriculture Technology, Inc. | Methods for efficient maize genome editing |
| KR20250107288A (ko) | 2017-10-16 | 2025-07-11 | 더 브로드 인스티튜트, 인코퍼레이티드 | 아데노신 염기 편집제의 용도 |
| WO2019089803A1 (en) | 2017-10-31 | 2019-05-09 | The Broad Institute, Inc. | Methods and compositions for studying cell evolution |
| EP3704245A1 (en) | 2017-11-01 | 2020-09-09 | Novartis AG | Synthetic rnas and methods of use |
| IL317505A (en) * | 2017-11-10 | 2025-02-01 | Univ Massachusetts | CRISPR-directed delivery platforms |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| AU2019207409B2 (en) | 2018-01-12 | 2023-02-23 | Basf Se | Gene underlying the number of spikelets per spike qtl in wheat on chromosome 7a |
| WO2019165168A1 (en) | 2018-02-23 | 2019-08-29 | Pioneer Hi-Bred International, Inc. | Novel cas9 orthologs |
| KR102907245B1 (ko) | 2018-03-14 | 2026-01-05 | 에디타스 메디신, 인코포레이티드 | 혈색소병증 치료를 위한 시스템 및 방법 |
| EP3592140A1 (en) | 2018-03-19 | 2020-01-15 | Regeneron Pharmaceuticals, Inc. | Transcription modulation in animals using crispr/cas systems |
| JP6614622B2 (ja) * | 2018-04-17 | 2019-12-04 | 国立大学法人名古屋大学 | 植物ゲノム編集方法 |
| KR102922694B1 (ko) | 2018-04-19 | 2026-02-03 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 유전자 편집을 위한 조성물 및 방법 |
| US12157760B2 (en) | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
| EP3823633A4 (en) | 2018-06-29 | 2023-05-03 | Editas Medicine, Inc. | SYNTHETIC LEAD MOLECULES, COMPOSITIONS AND METHODS RELATED THERETO |
| US12522807B2 (en) | 2018-07-09 | 2026-01-13 | The Broad Institute, Inc. | RNA programmable epigenetic RNA modifiers and uses thereof |
| GB201813011D0 (en) | 2018-08-10 | 2018-09-26 | Vib Vzw | Means and methods for drought tolerance in crops |
| WO2020051562A2 (en) | 2018-09-07 | 2020-03-12 | Beam Therapeutics Inc. | Compositions and methods for improving base editing |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| WO2020123887A2 (en) | 2018-12-14 | 2020-06-18 | Pioneer Hi-Bred International, Inc. | Novel crispr-cas systems for genome editing |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| AU2020215730A1 (en) | 2019-01-31 | 2021-07-29 | Beam Therapeutics Inc. | Nucleobase editors having reduced non-target deamination and assays for characterizing nucleobase editors |
| CN120174005A (zh) | 2019-02-13 | 2025-06-20 | 比姆医疗股份有限公司 | 具有用于修饰靶标序列中核碱基的腺苷脱氨酶碱基编辑器的经修饰的免疫细胞 |
| EP3696189A1 (en) * | 2019-02-14 | 2020-08-19 | European Molecular Biology Laboratory | Means and methods for preparing engineered target proteins by genetic code expansion in a target protein selective manner |
| WO2020191233A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| EP4034138A4 (en) | 2019-09-27 | 2024-07-31 | Beam Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS |
| US20210095273A1 (en) * | 2019-09-30 | 2021-04-01 | Sigma-Aldrich Co. Llc | Modulation of microbiota compositions using targeted nucleases |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| JP2023508731A (ja) * | 2019-12-30 | 2023-03-03 | ライフエディット セラピューティクス，インコーポレイティド | Ｒｎａ誘導ヌクレアーゼ、その活性断片および多様体、ならびに使用方法 |
| JP7525140B2 (ja) * | 2020-01-31 | 2024-07-30 | 国立大学法人京都大学 | タンパク質翻訳の制御システム |
| IL297761A (en) | 2020-05-08 | 2022-12-01 | Broad Inst Inc | Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence |
| GB202007943D0 (en) * | 2020-05-27 | 2020-07-08 | Snipr Biome Aps | Products & methods |
| CA3196831A1 (en) | 2020-09-25 | 2022-03-31 | Beam Therapeutics Inc. | Fratricide resistant modified immune cells and methods of using the same |
| RU2749307C1 (ru) * | 2020-10-30 | 2021-06-08 | Федеральное государственное бюджетное научное учреждение "Всероссийский научно-исследовательский институт сельскохозяйственной биотехнологии" (ФГБНУ ВНИИСБ) | Новая компактная нуклеаза CAS9 II типа из Anoxybacillus flavithermus |
| WO2022116139A1 (zh) * | 2020-12-04 | 2022-06-09 | 中国科学院脑科学与智能技术卓越创新中心 | 一种检测细胞内源性低丰度基因和lncRNA水平的方法 |
| US12171813B2 (en) | 2021-02-05 | 2024-12-24 | Christiana Care Gene Editing Institute, Inc. | Methods of and compositions for reducing gene expression and/or activity |
| JP2024534945A (ja) | 2021-09-10 | 2024-09-26 | アジレント・テクノロジーズ・インク | 化学修飾を有するプライム編集のためのガイドｒｎａ |
| EP4426828A1 (en) | 2021-11-01 | 2024-09-11 | Tome Biosciences, Inc. | Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo |
| KR20240117571A (ko) | 2021-12-08 | 2024-08-01 | 리제너론 파마슈티칼스 인코포레이티드 | 돌연변이 마이오실린 질환 모델 및 이의 용도 |
| AU2022420615A1 (en) | 2021-12-22 | 2024-07-04 | Tome Biosciences, Inc. | Co-delivery of a gene editor construct and a donor template |
| WO2023205744A1 (en) | 2022-04-20 | 2023-10-26 | Tome Biosciences, Inc. | Programmable gene insertion compositions |
| WO2023225670A2 (en) | 2022-05-20 | 2023-11-23 | Tome Biosciences, Inc. | Ex vivo programmable gene insertion |
| WO2024020587A2 (en) | 2022-07-22 | 2024-01-25 | Tome Biosciences, Inc. | Pleiopluripotent stem cell programmable gene insertion |
| WO2024138194A1 (en) | 2022-12-22 | 2024-06-27 | Tome Biosciences, Inc. | Platforms, compositions, and methods for in vivo programmable gene insertion |
| WO2024234006A1 (en) | 2023-05-11 | 2024-11-14 | Tome Biosciences, Inc. | Systems, compositions, and methods for targeting liver sinusodial endothelial cells (lsecs) |
| WO2025050069A1 (en) | 2023-09-01 | 2025-03-06 | Tome Biosciences, Inc. | Programmable gene insertion using engineered integration enzymes |
| EP4677108A1 (en) | 2024-04-22 | 2026-01-14 | Basecamp Research Ltd | Method and compositions for detecting off-target editing |
| WO2025224182A2 (en) | 2024-04-23 | 2025-10-30 | Basecamp Research Ltd | Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6933378B2 (en) * | 1997-05-30 | 2005-08-23 | Joseph Atabekov | Methods for coexpression of more than one gene in eukaryotic cells |
| US6203986B1 (en) | 1998-10-22 | 2001-03-20 | Robert H. Singer | Visualization of RNA in living cells |
| RU2467069C2 (ru) * | 2006-03-09 | 2012-11-20 | Зе Скрипс Ресеч Инститьют | Система экспрессии компонентов ортогональной трансляции в эубактериальной клетке-хозяине |
| US8481272B2 (en) * | 2006-08-04 | 2013-07-09 | Georgia State University Research Foundation, Inc. | Enzyme sensors, methods for preparing and using such sensors, and methods of detecting protease activity |
| CN101688241B (zh) | 2007-03-02 | 2015-01-21 | 杜邦营养生物科学有限公司 | 具有改善的噬菌体抗性的培养物 |
| WO2010011961A2 (en) | 2008-07-25 | 2010-01-28 | University Of Georgia Research Foundation, Inc. | Prokaryotic rnai-like system and methods of use |
| US20100076057A1 (en) | 2008-09-23 | 2010-03-25 | Northwestern University | TARGET DNA INTERFERENCE WITH crRNA |
| US9404098B2 (en) | 2008-11-06 | 2016-08-02 | University Of Georgia Research Foundation, Inc. | Method for cleaving a target RNA using a Cas6 polypeptide |
| US8586526B2 (en) | 2010-05-17 | 2013-11-19 | Sangamo Biosciences, Inc. | DNA-binding proteins and uses thereof |
| US10087431B2 (en) | 2010-03-10 | 2018-10-02 | The Regents Of The University Of California | Methods of generating nucleic acid fragments |
| MX2012013037A (es) | 2010-05-10 | 2013-07-29 | Univ California | Composiciones de endorribonucleasa y metodos de uso de las mismas. |
| WO2012164565A1 (en) | 2011-06-01 | 2012-12-06 | Yeda Research And Development Co. Ltd. | Compositions and methods for downregulating prokaryotic genes |
| US10323236B2 (en) * | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| GB201122458D0 (en) | 2011-12-30 | 2012-02-08 | Univ Wageningen | Modified cascade ribonucleoproteins and uses thereof |
| US20150166969A1 (en) | 2012-02-24 | 2015-06-18 | Fred Hutchinson Cancer Research Center | Compositions and methods for the treatment of hemoglobinopathies |
| WO2013130824A1 (en) | 2012-02-29 | 2013-09-06 | Sangamo Biosciences, Inc. | Methods and compositions for treating huntington's disease |
| WO2013141680A1 (en) | 2012-03-20 | 2013-09-26 | Vilnius University | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX |
| US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
| AU2013266968B2 (en) | 2012-05-25 | 2017-06-29 | Emmanuelle CHARPENTIER | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
| WO2014022702A2 (en) | 2012-08-03 | 2014-02-06 | The Regents Of The University Of California | Methods and compositions for controlling gene expression by rna processing |
| PL3360964T3 (pl) * | 2012-12-06 | 2020-03-31 | Sigma-Aldrich Co. Llc | Modyfikacja i regulacja genomu oparta na crispr |
| EP3031921B1 (en) * | 2012-12-12 | 2025-03-12 | The Broad Institute, Inc. | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| CN113355357B (zh) | 2012-12-12 | 2024-12-03 | 布罗德研究所有限公司 | 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化 |
| DK2931891T3 (da) * | 2012-12-17 | 2019-08-19 | Harvard College | Rna-styret modificering af menneskelige genomer |
| WO2014197748A2 (en) * | 2013-06-05 | 2014-12-11 | Duke University | Rna-guided gene editing and gene regulation |
-
2014
- 2014-07-08 EP EP19219620.2A patent/EP3666892A1/en active Pending
- 2014-07-08 RU RU2019132195A patent/RU2748433C2/ru active
- 2014-07-08 RU RU2016104161A patent/RU2704981C2/ru active
- 2014-07-08 SG SG11201600060VA patent/SG11201600060VA/en unknown
- 2014-07-08 WO PCT/US2014/045700 patent/WO2015006294A2/en not_active Ceased
- 2014-07-08 CA CA3218040A patent/CA3218040A1/en active Pending
- 2014-07-08 KR KR1020167003074A patent/KR102285485B1/ko active Active
- 2014-07-08 SG SG10201800213VA patent/SG10201800213VA/en unknown
- 2014-07-08 JP JP2016525414A patent/JP6718813B2/ja active Active
- 2014-07-08 SG SG10201913015XA patent/SG10201913015XA/en unknown
- 2014-07-08 US US14/903,728 patent/US10329587B2/en active Active
- 2014-07-08 CN CN201910999512.6A patent/CN110819658B/zh active Active
- 2014-07-08 IL IL282489A patent/IL282489B/en unknown
- 2014-07-08 EP EP14823626.8A patent/EP3019204B1/en active Active
- 2014-07-08 BR BR112016000571-6A patent/BR112016000571B1/pt active IP Right Grant
- 2014-07-08 CN CN201480048712.9A patent/CN105517579B/zh active Active
- 2014-07-08 KR KR1020217024118A patent/KR102481330B1/ko active Active
- 2014-07-08 AU AU2014287397A patent/AU2014287397B2/en active Active
- 2014-07-08 CA CA2917639A patent/CA2917639C/en active Active
-
2015
- 2015-03-31 US US14/674,895 patent/US9587252B2/en active Active
-
2016
- 2016-01-06 IL IL24347616A patent/IL243476B/en active IP Right Grant
-
2019
- 2019-05-14 US US16/411,793 patent/US11649469B2/en active Active
- 2019-10-29 IL IL270259A patent/IL270259B/en active IP Right Grant
- 2019-12-27 JP JP2019238875A patent/JP7153992B2/ja active Active
-
2020
- 2020-01-09 AU AU2020200163A patent/AU2020200163C1/en active Active
-
2021
- 2021-05-20 RU RU2021114286A patent/RU2771583C1/ru active
- 2021-11-25 AU AU2021273624A patent/AU2021273624C1/en active Active
-
2022
- 2022-10-03 JP JP2022159833A patent/JP2022176275A/ja active Pending
-
2023
- 2023-04-06 US US18/296,446 patent/US12577590B2/en active Active
-
2024
- 2024-10-28 AU AU2024227690A patent/AU2024227690A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016523560A5 (https=) | ||
| AU2021273624C1 (en) | Orthogonal Cas9 proteins for RNA-guided gene regulation and editing | |
| IL272193A (en) | Genome engineering | |
| HK40031893A (en) | Orthogonal cas9 proteins for rna-guided gene regulation and editing | |
| HK1217907B (en) | Orthogonal cas9 proteins for rna-guided gene regulation and editing | |
| NZ754836B2 (en) | Orthogonal cas9 proteins for rna-guided gene regulation and editing | |
| NZ754837B2 (en) | Orthogonal cas9 proteins for rna-guided gene regulation and editing | |
| NZ716605B2 (en) | Orthogonal cas9 proteins for rna-guided gene regulation and editing |